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SUMMARY

Generation of insulin-secreting b cells in vitro is a promising approach for diabetes cell therapy. Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) are differentiated to b cells
(SC-b cells) and mature to undergo glucose-stimulated insulin secretion, but molecular regulation of this
defining b cell phenotype is unknown. Here, we show that maturation of SC-b cells is regulated by the transcription factor SIX2. Knockdown (KD) or knockout (KO) of SIX2 in SC-b cells drastically limits glucose-stimulated insulin secretion in both static and dynamic assays, along with the upstream processes of cytoplasmic
calcium flux and mitochondrial respiration. Furthermore, SIX2 regulates the expression of genes associated
with these key b cell processes, and its expression is restricted to endocrine cells. Our results demonstrate
that expression of SIX2 influences the generation of human SC-b cells in vitro.

INTRODUCTION
Pancreatic b cells regulate blood glucose levels by secreting a
precise amount of insulin in response to changes in extracellular
glucose, and death or dysfunction of these cells results in diabetes. Transplantation of insulin-secreting cells shows promise
to be an effective treatment for diabetes (Bellin et al., 2012;
McCall and Shapiro, 2012; Millman and Pagliuca, 2017), and a
small number of patients who have received such implants
from cadaveric donors remain normoglycemic for years. Scarcity and high variability of donor islets limit this approach, however (McCall and Shapiro, 2012).
To overcome this limitation, strategies for specifying b cells
from human embryonic stem cells (hESCs) in vitro have been
described recently (Pagliuca et al., 2014; Rezania et al., 2014).
These approaches use growth factors and small molecules to
mimic native b cell development by first specifying definitive
endoderm (D’Amour et al., 2005), followed by the generation of
NKX6-1+ pancreatic progenitors (D’Amour et al., 2006). These
progenitors are specified into endocrine via the expression of
NEUROG3 (NGN3) (Gu et al., 2002) and are subsequently
matured into SC-b cells and other islet endocrine cell types
(Veres et al., 2019). More recent studies have defined conditions
that greatly improve the functional maturation of SC-b cells,
achieving first- and second-phase insulin secretion (Hogrebe
et al., 2020; Velazco-Cruz et al., 2019). While a large number of
genes that temporally correlate with maturation have been identified (Nair et al., 2019; Veres et al., 2019), the molecular mechanisms controlling this functional maturation are unclear,
hampering further improvements in function.

To investigate the functional maturation of human b cells
in vitro, we studied the homeobox transcription factor SIX2 during differentiation to SC-b cells. SIX2 is not expressed in rodent b
cells (Segerstolpe et al., 2016; Xin et al., 2016), which limits the
use of conventional approaches for its study, including
commonly used insulinoma cell lines and animal models. SIX2
has recently been identified as being expressed in human b cells
and linked to type 2 diabetes and aging (Arda et al., 2016; Hachiya et al., 2017; Kim et al., 2011; Spracklen et al., 2018).
Here, we report that SIX2 is key for generating functional SC-b
cells in vitro. Using short hairpin RNA (shRNA) and CRISPR-Cas9
to knock down (KD) SIX2 expression or knock out (KO) the SIX2
gene, respectively, we show that both static and dynamic
glucose-stimulated insulin secretion are severely hampered
with reduced SIX2 expression. Upstream processes of cytoplasmic calcium flux and mitochondrial respiration are similarly
reduced. Using RNA sequencing, we observe a large number
of genes associated with maturation and b cell function to be
reduced with the KD of SIX2, including gene sets associated
temporally with SC-b cell maturation in vitro from other research
groups.
RESULTS
SIX2 Is Crucial for Acquisition of Glucose-Stimulated
Insulin Secretion
Since SIX2 is expressed in human b cells, but its regulatory role
during b cell differentiation and maturation is uncharacterized,
we measured its gene expression during our 6-stage differentiation protocol (Figure 1A). We observed a notably large increase in
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Figure 1. SIX2 Controls Glucose-Stimulated
Insulin Secretion in Human SC-b Cells
(A) Schematic of hESC differentiation process.
(B) Real-time PCR measurements of SIX2 in undifferentiated hESCs and at the end of each stage
of the differentiation. Data are presented as the
fold change relative to stage 6 cells. n = 3.
(C) Real-time PCR measurements of SIX2 as a
function of time in stage 6 plotted against insulin
secretion of sampled cells placed in 20 mM
glucose for 1 h. n = 4.
(D) Dynamic glucose-stimulated insulin secretion
of stage 6 cells transfected with control shRNA (shctrl; n = 3) or shRNA targeting SIX2 (sh-SIX2-1; n =
4). Cells are perfused with 2 mM glucose, except
when indicated, in a perifusion chamber.
(E) Static glucose-stimulated insulin secretion of
sh-ctrl or sh-SIX2-1 transduced stage 6 cells. n = 4.
(F) Dynamic glucose-stimulated insulin secretion
of wild-type (WT) (n = 4), KO-SIX2-1 (n = 3 technical
replicates), or KO-SIX2-2 (n = 3 technical replicates) stage 6 cells.
(G) Static glucose-stimulated insulin secretion of
WT, KO-SIX2-1, or KO-SIX2-2 stage 6 cells. n = 4.
All data in (B)–(E) were generated with cells from
protocol 1 and all data in (F) and (G) were generated with cells from protocol 2.
*p < 0.05, **p < 0.01, ****p < 0.0001 by 2-way paired
(for low-high glucose comparison) or unpaired (for
high-high glucose comparison) t test. Error bars
represent s.e.m.
See also Figure S1.

expression during the maturation of endocrine progenitors to
SC-b cells (Figure 1B). Closer inspection of stage 6 revealed
that the gene expression of SIX2 increased 32.5 ± 0.9 times during the first 11 days, correlating with increases in insulin protein
secretion per cell for the same time period (Figure 1C).
To further study SIX2 using our SC-b cell platform, we generated 2 lentiviruses carrying shRNAs (sh-SIX2-1 and sh-SIX2-2) to
KD the expression of SIX2 (Figures S1A and S1B). For these KD
studies, we transduced cells on the first day of stage 6 to limit the
emergence of SIX2 expression with time. KD of SIX2 in differentiating hESCs (HUES8) and human induced pluripotent stem

2 Cell Reports 31, 107687, May 26, 2020

cells (hiPSCs) (1013-4FA) lines resulted
in significant reductions in both dynamic
and static glucose-stimulated insulin
secretion assays (Figures 1D, 1E, and
S1C–S1F). While peaks in the dynamic insulin secretion profile resembling firstand second-phase insulin secretion
were still observed, the overall amount
of insulin secreted per DNA was 4.2 ±
1.2 times lower at high glucose with
SIX2 KD (Figure 1D). Similarly, for the
static assay, while the cells still responded, albeit more weakly, to glucose
by secreting elevated insulin, insulin
secretion per cell was 4.7 ± 0.8 times
lower at high glucose with SIX2 KD
(Figure 1E). We do note that the magnitude of the relative insulin
secretion at low glucose differed between static and dynamic
assays, perhaps due to fluid shear or paracrine effects.
Since the KD studies supported a connection between SIX2
and the acquisition of SC-b cell function, we used CRISPRCas9 to KO SIX2 by deleting the SIX2 coding sequence to create
2 homozygous KO hESC lines (KO-SIX2-1 and KO-SIX-2) to
ensure the complete absence of SIX2 (Figures S1G–S1K).
Similar to the KD studies, KO of SIX2 also resulted in significant
reductions in both dynamic and static glucose-stimulated insulin
secretion assays (Figures 1F and 1G). In contrast to the KD
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Figure 2. Subtypes of Differentiated Stage 6
Cells Express SIX2
(A) Immunostaining of SIX2 with the b cell markers
NKX6-1 and C-peptide at the end of stages 5 (left)
and 6 (right).
(B) Flow cytometric quantification of co-expression of C-peptide with SIX2. n = 4.
(C) Immunostaining of SIX2 with a panel of
pancreatic markers at the end of stage 6 with the
exception of NGN3/SIX2, which was stained
3 days into stage 5.
(D) Flow cytometric quantification of stage 6 cells
staining for C-peptide, NKX6.1, and chromogranin
A using sh-ctrl and sh-SIX2-1 transduced cells. n =
6. ***p < 0.001 by 2-way unpaired t test.
(E) Schematic summary of marker progression in
stages 5 and 6.
Scale bar, 25 mm. Error bars represent s.e.m.
See also Figure S2.

glucose for SIX2 KO (Figures 1F and 1G).
Arda et al. (2016) showed that SIX3, a
different transcription factor within the
SIX family, is enriched in adult human islets relative to juvenile islets and that its
expression is associated with increased
b cell function. We measured the expression profile of SIX3 during our SC-b cell
differentiation (Figure S2A). While
increased expression during early definitive endoderm induction was measured,
SIX3 expression was low or undetected
at the end of the protocol, and KD or KO
of SIX2 did not alter SIX3 expression (Figure S2B). These data establish SIX2 as a
potent regulator of human b cell acquisition of functional maturation in vitro,
demonstrating that SIX2 is necessary for
first- and second-phase insulin secretion
in response to glucose. SIX2 is not
required for insulin production and
secreting, but the lack of SIX2 reduced insulin secretion when cells are exposed to
high glucose.

studies, SIX2 KO resulted in no first- and second-phase dynamic
insulin responses to high glucose and no response to glucose in
the static assay. In addition, the overall amount of insulin
secreted per DNA was 4.2 ± 0.7 times lower in the dynamic assay
and per cell was 6.2 ± 1.5 times lower in the static assay at high

Characterization of SIX2
Expression During SC-b Cell
Differentiation
Next, we characterized the expression
profile of SIX2 protein throughout the differentiation process. Using immunofluorescence, we did not detect SIX2 expression in C-peptide+ cells at the beginning
of stage 6, but after 11 days in stage 6, some C-peptide+ cells expressed nuclear SIX2 (Figure 2A). Virtually all SIX2+ cells co-expressed NKX6-1 (Figure 2A). With flow cytometry, we demonstrated that 25.1% ± 0.5% of the C-peptide+ cells coexpressed SIX2 in stage 6 (Figure 2B). However, some SIX2+
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cells were observed outside the C-peptide+ population and are
of unknown identity. We also observed that SIX2 was restricted
to NKX2-2+ and synaptophysin+ (SYN) cells in stage 6 (Figure 2C), indicating that the expression of SIX2 is restricted to
this endocrine cell population. In spite of this, SIX2 was not
observed in NGN3+ cells during stage 5 (Figure 2C), even with
many of these cells co-expressing NKX6-1 (Figure S2C). Virtually
all SIX2+ cells also co-expressed other pancreatic markers, such
as ISL1, PAX6, and PDX1 (Figure 2C). Furthermore, the a cell
hormone-expressing glucagon+ (GCG) cells did not express
SIX2, and SOX9+ progenitors were absent in the stage 6 population (Figure 2C). KD of SIX2 reduced the fraction of cells expressing C-peptide+ and co-expressing C-peptide with NKX6.1 (Figures 2D and S2D), demonstrating an effect on cell fate, while
KO of SIX2 did not affect pancreatic progenitors (Figure S2E).
These data demonstrate that SIX2 protein expression is only detected in the endocrine population and influences final cell fate.
Transcriptional Profiling of SIX2 KD cells
To further explore the role of SIX2 on SC-b cells, we used RNA
sequencing to measure the transcriptome of stage 6 cells transduced with shRNA to KD SIX2 expression. A large number
(10,421) of genes were significantly (adjusted p < 0.05) affected
by the KD of SIX2, including individual genes associated with b
cell function and off-target non-b cell genes (Figures 3 and S3;
Table S1). Of the significantly different genes, 633 were enriched
in the control cells and 509 were enriched in the SIX2 KD cells by
at least a factor of 2 (Figure 3B).
Several gene sets important for b cells, such as those correlated with b cell fate, b cell maturation, exocytosis, potentiation
of insulin secretion, and maturation, were controlled by SIX2 (Figures 3C–3E, S3A, andS3B; Tables S2 and S3). The specific established gene sets that are well known included the gene sets b cell
enriched (CARTPT, IAPP, GLP1R, GCK, ABCC8, PAX6, INS), calcium signaling (HPCAL4, CAMKK2A, CACNA1S), potassium
channels (ATP1A3, KCNN3, KCNMA1), cyclic AMP (cAMP)
signaling (ADCY8, CREB5, ADCY3), and protein kinase C (PKC)
signaling (PRKC3, PRKCH, PRKCA). In addition, undesirable
off-target markers, including liver (ALB, AFP), anterior endoderm
(SOX2), and posterior endoderm (CDX2), and gene sets, such as
glycolysis, were enriched in the SIX2 KD cells. We validated RNA
sequencing results with a subset of relevant genes using realtime PCR in the 1013-4FA hiPSC background (Figure S3C). We
compared our RNA sequencing data to recent gene sets identified in Veres et al. (2019) and Nair et al. (2019) as positively correlating with time in the final stage of differentiation of SC-b cells
in vitro. We found that our SIX2 KD data were statistically associated with the Veres et al. and Nair et al. gene sets (Figures 3C, 3D,
S3B, and S4; Table S3). Specifically, the KD of SIX2 repressed
many of the genes that increased expression in Veres et al.
(2019) and Nair et al. (2019), suggesting that many of these identified genes are controlled by SIX2. These data support the
conclusion that SIX2 controls the expression of many b cell genes
related to normal physiological function and differentiation.
Physiological Profiling of SIX2 KD SC-b Cells
We followed up on key b cell processes implicated by the SIX2
KD RNA sequencing data. First, we found that KD of SIX2
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reduced insulin content and INS gene expression, but it did not
affect insulin processing (Figures 4A–4C and S4A). Second, we
assessed mitochondrial respiration and glycolysis because
switching from glycolysis to mitochondrial respiration is necessary for the maturation and normal physiological function of b
cells (Nair et al., 2019). The Seahorse XFe24 extracellular flux
assay was used to measure the oxygen consumption rate
(OCR) and the extracellular acidification rate (ECAR), respectively. KD of SIX2 resulted in a decreased OCR and ratio of
OCR to ECAR (Figures 4D, 4E, and S4C). Cytoplasmic calcium
flux was also evaluated, as the influx of calcium is necessary
before insulin secretion and is triggered by glucose-induced depolarization in b cells (Rutter and Hodson, 2013). KD of SIX2
slightly decreased glucose-stimulated and greatly decreased
KCl-stimulated increases in cytoplasmic calcium as determined
with Fluo-4 AM stained cells (Figure 4F). These data are consistent with decreased glucose-stimulated insulin secretion (Figures 1D–1G and S1C–S1F) and the RNA sequencing analysis
(Figure 3), indicating that SIX2 plays a key role in the metabolism
and upstream signaling relating to the functional maturation of
SC-b cells.
Finally, we explored other known insulin secretagogues,
observing that while SIX2 KD cells were able to respond to all
treatments, the amount of insulin secretion was much lower
than the control (Figure 4G). Stimulation with KCl and 3-isobutyl-1-methylxanthine (IBMX) demonstrated that SIX2 KD cells
were capable of elevating insulin secretion, but glucose-dependent secretion was severely impaired without SIX2. Furthermore,
considering the large amount of insulin secretion with treatments
targeting downstream processes, particularly depolarization
(KCl) and cAMP accumulation (IBMX), upstream mechanisms
appear more affected by SIX2 KD, namely glucose sensing
and metabolism. In addition to defects in glucose-stimulated insulin secretion, SC-b cells with KD of SIX2 have defects in insulin
content, mitochondrial respiration, calcium signaling, and
response to a wide array of secretagogues.
DISCUSSION
Here, we demonstrate that SIX2 influences the generation human SC-b cells in vitro. Increases in SIX2 expression correlates
with increases in insulin secretion as SC-b cells mature during
stage 6 of the differentiation protocols. KD or KO of SIX2 dramatically reduces glucose-stimulated insulin secretion, including
first- and second-phase dynamic insulin release and the total
amount of insulin released from the cells. Expression of SIX2 protein appears to be restricted to endocrine cells. RNA sequencing
of cells with the KD of SIX2 reveals that a large number of gene
sets associated with b cells and off-targets are negatively
affected, including recently defined gene sets of maturing SCb cells. We confirmed the physiological effects of many of these
gene sets by measuring reductions in insulin content, insulin
gene expression, mitochondrial respiration, calcium flux, and insulin secretion in response to compounds that block the KATP
channel (tolbutamide), accumulate cAMP (IBMX), activate
GLP1R (Exendin-4), and depolarize the membrane (KCl).
A major goal in regenerative medicine is to generate fully
mature replacement cells differentiated from stem cells.
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Figure 3. SIX2 Regulates Important b Cell Genes and Gene Sets
(A) Heatmap of 1,000 most differentially expressed genes between stage 6 cells transduced with sh-ctrl and sh-SIX2-1 by p value. n = 6.
(B) Volcano plot showing all differentially expressed genes. Genes with at least a 2-fold change (FC) are in black. Genes of particular interest are highlighted.
(C) Selected enriched gene sets for important b cell processes from the Molecular Signatures Database. Also included 2 custom gene sets comprising 76 genes
identified in Veres et al. (2019) and the top 424 genes identified in Nair et al. (2019) positively correlating with time and maturation in vitro. NES, normalized
enrichment score.
(D) Enrichment plots from the shown gene sets.
(E) FCs from genes within enriched b cell-related gene sets.
See also Figure S3 and Tables S1–S3.

However, while many differences often exist in the function and
gene expression of stem cell-differentiated cells, often referred
to as the maturation phenotype specific to the differentiated cells
in question, identifying specific parameters on which to focus is
often difficult due to a lack of understanding of human developmental biology. In the case of SC-b cells, many genes and pathways have been focused on and studied in the context of

improving these cells, including YAP (Rosado-Olivieri et al.,
2019), the ROCKII pathway (Ghazizadeh et al., 2017), the
transforming growth factor b (TGF-b) pathway (Velazco-Cruz
et al., 2019), and the cytoskeleton (Hogrebe et al., 2020).
Further studies have connected diabetic pathogenetic variants
with impairments in polyhormonal endocrine or SC-b cells,
including INS (Balboa et al., 2018; Ma et al., 2018), HNF1-a
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Figure 4. SIX2 Affects Insulin Content, Mitochondrial Respiration, Cytoplasmic Calcium Flux, and Response to Secretagogues in SC-b cells
(A) Insulin content for stage 6 cells. n = 12. ****p < 0.0001 by 2-way unpaired t test.
(B) Proinsulin:insulin content ratio for stage 6 cells. n = 12. ns (non-significant) by 2-way unpaired t test.
(C) Real-time PCR measurements of INS gene expression for stage 6 cells. n = 4. *p < 0.05 by 2-way unpaired t test.
(D) OCR measurements under basal conditions and after sequential injections of oligomycin (OM), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP), and antimycin A with rotenone (AA/R). n = 10 for sh-ctrl and n = 9 for sh-SIX2-1.
(E) Calculated OCR:ECAR ratio under basal conditions. n = 10 for sh-ctrl and n = 9 for sh-SIX2-1. ****p < 0.0001 by 2-way unpaired t test.
(F) Cytosolic calcium signaling in response to high glucose (20 mM) and high KCl (30 mM) treatment relative to low glucose (2 mM, Fo) for Fluo-4 AM. Violin plots
show distribution of cellular responses for sh-ctrl (n = 232) and sh-SIX2-1 (n = 276) transduced cells with median and quartiles marked with dashed lines. ****p <
0.0001 by 2-way unpaired t test.
(G) Static glucose-stimulated insulin secretion with cells with 2 mM glucose, 20 mM glucose, or 20 mM glucose with the indicated compound. n = 3. ns, ** or yyp <
0.01, *** or yyyp < 0.001, **** or yyyyp < 0.0001 by 2-way unpaired t test. * indicates comparison within same compound treatment. y indicates comparison with low
glucose with same shRNA treatment.
Error bars represent s.e.m.
See also Figure S4.

(Cardenas-Diaz et al., 2019), WFS1 (Maxwell et al., 2020; Shang
et al., 2014), ZNT8 (Dwivedi et al., 2019), NEUROD1 (Romer
et al., 2019), and GCK (Hua et al., 2013).
In contrast, here, we focus on the role of SIX2 in the differentiation to and maturation of SC-b cells and establish a critical
connection between this transcription factor and the generation
and functional maturation of SC-b cells, particularly regarding
glucose-stimulated insulin secretion. Arda et al. (2016) studied
both SIX2 and SIX3 in the human insulinoma EndoC-bH1 cell
line and found overexpressing SIX3 but not SIX2 to increase insulin secretion and content in addition to increased expression of
these genes in adult versus juvenile islets, supporting differing
roles for these transcription factors. Our study differs from that
of Arda et al. (2016) in several respects. We studied SIX2 in the
context of differentiating and maturing SC-b cells, the process
of which has increasing SIX2 expression as cells mature with
time, a considerably different developmental context than that
modeled by EndoC-bH1 cells. Furthermore, our study investigates many other aspects of b cell phenotype not explored by
Arda et al., including demonstrating that both first- and second-phase dynamic insulin secretion are eliminated with KO of
SIX2, made possible by our recent discoveries of generating
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SC-b cells using these functional characterizations (VelazcoCruz et al., 2019), indexing transcriptional changes with KD of
SIX2, and showing how mechanisms of b cell glucose sensing,
respiration, and calcium flux are disrupted with KD of SIX2.
Furthermore, while our data demonstrate the importance of
SIX2 in SC-b cells, this transcription factor is in the presence of
many other transcription factors that are important for the b
cell phenotype, including PDX1, NKX6-1, NKX2-2, and
NEUROD1 (Hogrebe et al., 2020). Understanding the molecular
interactions and regulatory network of SIX2 with these transcription factors would be valuable in future studies.
Differences in transcriptional regulation in rodent and human b
cells are well known (Benner et al., 2014). Since SIX2 expression
is restricted to human b cells (Segerstolpe et al., 2016; Xin et al.,
2016), focused studies on human cell model systems, such as
that provided by our in vitro differentiation platform, are essential
in the investigation of cell maturation and disease. Proper understanding of the molecular mechanisms that control human b cell
maturation is necessary for developing further improvements in
SC-b cell technologies for diabetes cell-replacement therapies.
As only a fraction of C-peptide+ cells currently express SIX2 in
our study, increased co-expression could result in differentiated
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populations with increased function and utility for cell therapy.
Further study into the role of SIX2 could reveal new insights
into increasing the functional maturation of SC-b cells and the
regulation of expression of other b cell genes, such as MAFA
(Nair et al., 2019; Velazco-Cruz et al., 2019), or b cell failure in
type 2 diabetes.
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BioRep
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Bio-Gel P-4
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jeffrey R.
Milman (jmillman@wustl.edu).
Materials Availability
shRNA plasmids used in this study are from the TRC shRNA library and available from the RNAi Core at Washington University in St.
Louis.
HUES8 cell line is available through the Harvard Stem Cell Institute (HCSI).
SIX2 KO cell lines are made available upon request to Lead Contact.
Data and Code Availability
The RNA sequencing data generated in this study is made available at the Gene Expression Omnibus (GEO). The accession number
for the raw and processed data reported in this paper is GEO: GSE147737.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Culture of undifferentiated hESCs and differentiation to Stage 6 cells
Cell culture was performed as we previously described (Hogrebe et al., 2020; Millman et al., 2016; Velazco-Cruz et al., 2019). This
work was performed with the approval of the Washington University School of Medicine Embryonic Stem Cell Research Oversight
Committee (ESCRO). The HUES8 hESC and 1013-4FA hiPSC lines was generously provided by Dr. Douglas Melton (Harvard University) and has been published on previously (Hogrebe et al., 2020; Velazco-Cruz et al., 2019). All data is with the HUES8 cell line unless
otherwise noted to be 1013-4FA. For differentiation protocol 1 (Velazco-Cruz et al., 2019), which was used unless otherwise noted,
undifferentiated HUES8 were cultured in mTeSR1 (StemCell Technologies; 05850) in 30-mL spinner flasks (REPROCELL;
ABBWVS03A) on a rotator stir plate (Chemglass) at 60 RPM in a humidified 37 C 5% CO2 tissue culture incubator. Stem cells
were passaged every 3 days by single cell dispersion using Accutase (StemCell Technologies; 07920), viable cells counted with
Vi-Cell XR (Beckman Coulter), and seeded at 6 3 105 cells/mL in mTeSR1+ 10 mM Y27632 (Abcam; ab120129). The media was
then changed as outlined in Table S4 to induce differentiation. For differentiation protocol 2 (Hogrebe et al., 2020), which was
used for the KO studies and 1013-4FA differentiations, undifferentiated pluripotent stem cells were cultured in mTeSR1 on plates
coated with Matrigel (Corning; 356230) in a humidified 37 C 5% CO2 tissue culture incubator. Stem cells were passaged every
4 days single cell dispersion using TrypLE (Life Technologies; 12-604-039), viable cells counted with Vi-Cell XR, and seeded at
5.2 3 105 cells/cm2 in mTeSR1+ 10 mM Y27632. The media was then changed as outlined in Table S4 to induce differentiation.
On stage 6 day 1 of protocol 1 and stage 6 day 7 of protocol 2 cells were single cell dispersed using TrypLE (Life Technologies;
12-604-039; 15-minute incubation for protocol 1, 6-minute incubation for protocol 2). Following single cell dispersion cells were
re-aggregated by seeding 5 million cells in 5 mL of stage 6 media into a well of a 6-well plate placed on an orbi-shaker (Benchmark)
rotating at 100 RPM; clusters were allowed to re-aggregate and media was changed 48 hours post seeding.
METHOD DETAILS
Real-time PCR
Measurements were performed as we previously described (Velazco-Cruz et al., 2019). RNeasy Mini Kit (QIAGEN; 74016) with DNase
treatment (QIAGEN; 79254) was used for RNA extraction. High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems;
4368814) was used to make cDNA. PowerUp SYBR Green Master Mix (Applied Biosystems; A25741) on a StepOnePlus (Applied
Biosystems) was used to perform the real-time PCR reactions. Melting curves were ran for each primer to determine specificity of
amplification. DDCt methodology with TBP normalization was used for analysis. For samples undetected using real-time PCR CT
values where set to 40 in analysis. Primer sequences used were (gene, forward primer, reverse primer): INS, CAATGC
CACGCTTCTGC, TTCTACACACCCAAGACCCG; TBP, GCCATAAGGCATCATTGGAC, AACAACAGCCTGCCACCTTA; SIX2,
AAGGCACACTACATCGAGGC, CACGCTGCGACTCTTTTCC; SIX3, CTGCCCACCCTCAACTTCTC, GCAGGATCGACTC
GTGTTTGT; IAPP, ACATGTGGCAGTGTTGCATT, TCATTGTGCTCTCTGTTGCAT; UCN3, TGTAGAACTTGTGGGGGAGG,
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GGAGGGAAGTCCACTCTCG; ABCC8, GCCCACGAAAGTTATGAGGA, AAGGAGATGACCAGCCTCAG; GCK, ATGCTGGACGACA
GAGCC, CCTTCTTCAGGTCCTCCTCC; GLP1R1, GGTGCAGAAATGGCGAGAATA, CCGGTTGCAGAACAAGTCTGT; HOPX, GA
GACCCAGGGTAGTGATTTGA, AAAAGTAATCGAAAGCCAAGCAC; NEFL, ATGAGTTCCTTCAGCTACGAGC, CTGGGCATCAAC
GATCCAGA; CAMK2A, GCTCTTCGAGGAATTGGGCAA, CCTCTGAGATGCTGTCATGTAGT; ALB,
CCTTTGGCACAATGAAGTGGGTAACC, CAGCAGTCAGCCATTTCACCATAGG; CDX2, CCTCTGAGATGCTGTCATGTAGT,
GGTGATGTAGCGACTGTAGTGAA; AFP, TGTACTGCAGAGATAAGTTTAGCTGAC, CCTTGTAAGTGGCTTCTTGAACA
KD of SIX2
Gene KD was performed similar to as we previously described (Velazco-Cruz et al., 2019). pLKO.1 TRC plasmids containing shRNA
sequences targeting GFP (sh-ctrl) and human SIX2 (sh-SIX2-1 and sh-SIX2-2) were received from the RNAi Core at the Washington
University. sh-ctrl, GCGCGATCACATGGTCCTGCT; sh-SIX2-1, CAACGAGAACTCCAATTCTAA; sh-SIX2-2, GAGCACCTTCACAA
GAATGAA. Viral particles were generated using Lenti-X 293T cells (Takara; 632180) cultured in DMEM (MilliporeSigma; D6429)
with 10% heat inactivated fetal bovine serum (MilliporeSigma; F4135). Confluent Lenti-X 293T cells were transfected with 6 mg of
shRNA plasmid, 4.5 mg of psPAX2 (Addgene; 12260), and 1.5 mg pMD2.G (Addgene; 12259) packaging plasmids in 600 mL of
Opti-MEM (Life Technologies;31985-070) and 48 mL of Polyethylenimine ‘Max’ MW 40,000 Da (Polysciences; 24765-2). 16 hours
post transfection media was switched. Viral containing supernatant was collected at 96 hours post transfection and concentrated
using Lenti-X concentrator (Takara; 631232). Collected lentivirus was tittered using Lenti-X qRT-PCR Titration Kit (Takara;
631235). Lentiviral transduction occurred on the first day of Stage 6 by seeding 5 million dispersed single cells were into a well of
a 6-well plate with lentivirus particles MOI of 5, media was switched 16 hours post transduction. psPAX2 and pMD2.G were a gift
from Didier Trono.
Generation of SIX2 KO cell lines
CRISPR/Cas9 genome engineering of the HUES8 cell line was performed by the Washington University Genome Engineering & iPSC
Center. The high sequence similarity with other SIX genes limited the availability of high-quality gRNA sites, making conventional
frameshift introduction infeasible. Instead, a deletion strategy was employed for almost all the SIX2 coding sequence. Unique
genomic regions near the start and end of the SIX2 coding sequence were identified and guide RNAs were designed; 50 gRNA,
TCGGAGCTTCGTGGGACCCGCGG and 30 gRNA, CCACGAGGTTGGCTGACATGGGG. Two homozygous SIX2 KO HUES8 cell lines
were generated (KO-SIX2-1 and KO-SIX2-2). Validation of SIX2 KO was done by PCR using primers (GGGAGAACGAGTGA
GAAGCG, TGCGGGTCTTTCAGTACCTG) designed to amplify a 3368 bp sequence containing the coding region, deletion of which
will produce a 300 bp amplicon (‘‘Deletion primers’’). Validation was also done using primers (CAGTTCTGGGAGAGAAGAGAC,
GGGCTGGATTCTGTTCCCATA) targeting within the SIX2 coding sequence designed to amplify 300 bp in wt and failing to amplify
with successful deletion (‘‘Inside primers’’). Next generation sequencing was performed to further confirm KO.
Static glucose-stimulated insulin secretion
Measurements were performed as we previously described (Velazco-Cruz et al., 2019). The assay was performed in KRB buffer
(128 mM NaCl, 5 mM KCl, 2.7 mM CaCl2 1.2 mM MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES (GIBCO;
15630-080), and 0.1% BSA). Stage 6 clusters (20-30) were washed with KRB buffer and placed into transwells (Corning; 431752)
with 2 mM glucose KRB. After 1 hr of equilibration, the solution was replaced with 2 mM glucose KRB for a 1 hr low glucose challenge,
after which the solution was replace with 20 mM glucose alone or with
10 nM Extendin-4 (MilliporeSigma; E7144), 100 mM IBMX (MilliporeSigma; I5879), 300 mM Tolbutamide (MilliporeSigma; T0891), or
30 mM KCL (Thermo
Fisher; BP366500) KRB for a 1 hr high glucose challenge. Incubations were performed in a humidified incubator at 37 C 5% CO2.
Insulin was quantified with a human insulin ELISA (ALPCO; 80-INSHU-E10.1). Cell quantification was performed by dispersing with
trypLE and counting with the Vi-Cell XR.
Dynamic glucose-stimulated insulin secretion
Measurements were performed as previously described (Velazco-Cruz et al., 2019). Using an 8-channel peristaltic pump (ISMATEC;
ISM931C) together with 0.015’’ inlet/outlet two-stop tubing (ISMATEC; 070602-04i-ND) connected to 275-ml cell chamber (BioRep;
Peri-Chamber) and dispensing nozzle (BioRep; PERI-NOZZLE) using 0.04’’ connection tubbing (BioRep; Peri-TUB-040). Solutions,
tubing, and cells were maintained at 37 C using a water bath. Stage 6 clusters (20-30) were washed with KRB buffer and placed into
perifusion cell chamber between two layers of hydrated Bio-Gel P-4 polyacrylamide beads (Bio-Rad; 150-4124). After 90 min of equilibration with 2 mM glucose KRB, cells were subjected to the following at 100 mL/min: 12 min of 2 mM glucose KRB, 24 min of 20 mM
glucose KRB, and finally 12 min of 2 mM glucose KRB. Effluent was collected every 2 min. Insulin was quantified with a human insulin
ELISA (ALPCO; 80-INSHU-E10.1). DNA quantification was performed by lysing the cells and measuring with the Quant-iT Picogreen
dsDNA assay kit (Invitrogen; P7589). The lysis solution used consisted of 10 mM Tris (MilliporeSigma; T6066), 1 mM EDTA (Ambion;
AM9261), and 0.2% Triton X-100 (Acros Organics; 327371000).
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Immunostaining
Measurements were performed as we previously described (Velazco-Cruz et al., 2019). Stage 6 clusters were single-cell dispersed
with trypLE, plated overnight, and fixed with 4% paraformaldehyde (Electron Microscopy Science; 15714) for 30 min at RT. Samples
were treated for 30 min with blocking/permeabilizing/staining solution (5% donkey serum (Jackson Immunoresearch; 017-000-121)
and 0.1% Triton X-100 (Acros Organics; 327371000) in PBS). Samples were then incubated overnight at 4 C with primary antibody
diluted in staining solution, incubated 2 hr at 4 C with secondary antibodies diluted in staining solution, and stained with DAPI for
5 min. Nikon A1Rsi confocal microscope or Leica DMI4000 fluorescence microscope were used to take images. The antibodies
used are listed in Table S4.
Flow cytometry
Measurements were performed as we previously described (Velazco-Cruz et al., 2019). Clusters were single-cell dispersed with
TrypLE, fixed with 4% paraformaldehyde for 30 min at 4 C, incubated 30 min at 4 C in blocking/permeabilizing/staining solution,
incubated with primary antibodies in staining buffer overnight at 4 C, incubated with secondary antibodies in staining buffer for
2 hr at 4 C, resuspended in staining buffer, and analyzed on an LSRII (BD Biosciences) or X-20 (BD Biosciences). Dot plots and percentages were generated using FlowJo. The antibodies used are listed in Table S4.
RNA sequencing
RNA from sh-ctrl and sh-SIX2-1 transduced cells (n = 6 per condition) was extracted on Stage 6 Day 12 using RNeasy Mini Kit with
DNase treatment. Washington University Genome Technology Access Center performed library preparation, sequencing, and determination of differential expression. Libraries were indexed, pooled, and single-end 50 base pair reads were sequenced on one lane of
an Illumina HiSeq 3000 generating 25-30 million reads per sample. Reads were then aligned to the Ensembl release 76 top-level assembly with STAR. Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount. All
gene counts were imported into EdgeR5 and TMM normalization size factors were calculated. Ribosomal genes and genes not expressed in the smallest group size minus one, samples greater than one count-per-million were excluded from further analysis. The
TMM size factors and the matrix of counts were imported into Limma6. Weighted likelihoods based on the observed mean-variance
relationship of every gene and sample were calculated for all samples with the voomWithQualityWeights7. Differential expression
analysis was performed with a Benjamini-Hochberg false-discovery rate adjusted p values cut-off of less than or equal to 0.05. Hierarchical clustering and heatmaps were generated using Morpheus (https://software.broadinstitute.org/morpheus). To perform
gene set enrichment analyses normalized all gene counts were imported into GSEA software and the Molecular Signature Database
(MSigDB) Hallmark, KEGG, and Gene Ontology gene libraries were used to identify enriched gene sets (Subramanian et al., 2005).
In Vitro Beta Cell Maturation gene set was generated by combining Veres et al. (Veres et al., 2019) Stage 6 enriched genes logbase2
fold or greater (76 genes), and Nair et al. (Nair et al., 2019) b-clusters enriched genes (424 genes) with SIX2 removed.
Hormone content measurements
Measurements were performed as we previously described (Velazco-Cruz et al., 2019). Stage 6 cell clusters were collected, washed
with PBS, placed in acid-ethanol solution (1.5% HCl and 70% ethanol), stored at 20 C for 24 hours, vortexed, returned to 20 C for
24 additional hours, vortexed, and centrifuged at 2100 G for 15 min. The supernatant was collected and neutralized with an equal
volume of 1 M TRIS (pH 7.5). Human insulin and pro-insulin content were quantified using Human Insulin ELISA and Proinsulin ELISA
(Mercodia; 10-1118-01) respectively. Samples were normalized to cell counts made using the Vi-Cell XR.
OCR and ECAR measurements
Measurements were performed similar to as we previously reported (Millman et al., 2019). Stage 6 cell clusters were dispersed into a
single-cell suspension and plated 200,000 per well. After overnight incubation in S6 media, the media was replaced with RPMI-1640
(Sigma; R6504) with 7.4 pH and 20 mM glucose. The Seahorse XFe24 flux analyzer (Agilent) was used to measure OCR and ECAR.
After basal measurements, 3 mM oligomycin (Calbiochem; 1404-19-9), 0.25 mM carbonyl cyande-4-(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma; 270-86-5), and 1 mM rotenone (Calbiochem; 83-79-4) and 2 mM antimycin A (Sigma; 1397-94-0) where injected
sequentially and replicate measurements performed.
Cytoplasmic calcium measurements
Calcium measurements were done similar as previously reported (Kenty and Melton, 2015; Pagliuca et al., 2014). Stage 6 day 12
clusters were single cell dispersed by incubation in TrypLE for 10 minutes and plated down onto a Matrigel coated #1.5 glass bottom
96 well plate (Cellvis; 963-1.5H-N) and allowed to attach overnight. Following overnight attachment clusters were washed twice with
2 mM glucose KRB and incubated in 2 mM glucose KRB with 20 mM Fluo-4 AM (Invitrogen; F14201) for 45 min at 37 C. Cells were
washed twice with 2 mM glucose KRB, placed in 2 mM glucose KRB and incubated for 10 min at 37 C, then placed in a 37 C 5% CO2
humidified Tokai-hit stage-top on a Nikon Eclipse Ti inverted spinning disk confocal equipped with a Yokagawa CSU-X1 variable
speed Nipkow spinning disk scan head equipped with a motorized xy stage including nano-positioning piezo z-insert. Images
were acquired with the cells at 2 mM glucose KRB, 20 mM glucose KRB, and 20 mM glucose 30 mM KCl KRB. Analysis of calcium
flux image stack was performed using ImageJ with the StackReg package for correction.
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QUANTIFICATION AND STATISTICAL ANALYSIS
GraphPad Prism was used to calculate statistical significance for all non-RNA sequencing data. One- or two-sided paired or unpaired
t tests were used.
Differential expression analysis of RNA sequencing data was performed with a Benjamini-Hochberg false-discovery rate adjusted
p values cut-off of less than or equal to 0.05.
Error bars represent s.e.m. unless otherwise noted. Sample size (n) is specified in each figure caption and indicates biological replicates unless otherwise noted. Statistical parameters are stated in figure captions.
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Supplementary Figures

Figure S1. Validation of SIX2 KD and KO assessments. Related to Figure 1. (A) Real-time PCR measurements
of SIX2 gene expression for Stage 6 cells transduced with sh-ctrl, sh-SIX2-1, or sh-SIX2-2 for differentiated HUES8
(left) or 1013-4FA, made with protocol 2, (right) cells. n=3. (B) C-peptide and SIX2 immunostaining of stage 6 cells
made with protocol 2 transduced with sh-ctrl or sh-SIX2-1 in the 1013-4FA background. (C) Dynamic glucosestimulated insulin secretion of Stage 6 HUES8 cells transfected with control shRNA (sh-ctrl; n=4) or shRNA targeting
SIX2 (sh-SIX2-2; n=4). Cells are perfused with 2 mM glucose except when indicated in a perifusion chamber. (D)
Static glucose-stimulated insulin secretion of sh-ctrl or sh-SIX2-2 transduced Stage 6 HUES8 cells. n=5. (E) Dynamic
glucose-stimulated insulin secretion of Stage 6 1013-4FA cells made with protocol 2 transfected with control shRNA
(sh-ctrl; n=4) or shRNA targeting SIX2 (sh-SIX2-1; n=4). Cells are perfused with 2 mM glucose except when
indicated in a perifusion chamber. (F) Static glucose-stimulated insulin secretion of sh-ctrl or sh-SIX2-1 transduced
Stage 6 1013-4FA cells made with protocol 2. n=5. (G) CRISPR knock out strategy for the generation of the SIX2
KO HUES8 cell lines KO-SIX2-1 and KO-SIX2-2. HUES8 homozygous SIX2 KO clones were generated by deleting
the SIX2 coding sequence using two gRNAs target flanking regions of the SIX2 coding sequence. Also shown are the
primers used to validate deletion, “deletion primers” and “inside primers”. (H) PCR of SIX2 KO clones confirming
SIX2 coding sequence deletion. “Deletion primers” will produce 3368 bp amplicon for wt but only ~300 bp amplicon
with successful deletion. “Inside primers” will produce ~300 bp amplicon for wt but fail to amplify with successful
deletion. (I) Next generation sequencing confirming deletion of SIX2 coding sequence in KO cell lines. The entire
sequence between the 5’ and 3’ gRNA was absent (marked with red dash in reference). 1,085 total reads for KOSIX2-1 clone and 840 total reads for KO-SIX2-2 clone were sequenced and 0% wt gRNA target sequence were
detected and frame shifting indels totaled 100% for both clones. A few bp of SIX2 coding are leftover. (J) Real-time
PCR measurements of SIX2 gene expression for Stage 6 cells made with protocol 2 from wt or KO SIX2 HUES8
backgrounds. n=5. (K) C-peptide and SIX2 immunostaining of Stage 6 cells made with protocol 2 from wt or KO
SIX2 HUES8 backgrounds. Error bars represent s.e.m.

Figure S2. Additional evaluation of SIX3 and SIX2. Related to Figure 2. (A) Real-time PCR measurements of
SIX3 in undifferentiated hESCs and at the end of each stage of the differentiation. Data is presented as the fold change
relative to Stage 6 cells. All n=6, except PP2 n=3. (B) Real-time PCR measurements of SIX3 gene expression for
Stage 6 cells transduced with sh-ctrl or sh-SIX2-1 (n=4; left) or SIX2 wt and KO cells (n=5; right). ns=p>0.05. (C)
Immunostaining of NGN3 and NKX6-1 3 days into Stage 5. Scale bar=25 μm. (D) Flow cytometry plots of Stage 6
cells made with protocol 2 from the 1013-4FA background transduced with shRNA against GFP (control) and SIX2.
(E) Flow cytometry plots of Stage 5 day 1 cells made with protocol 2 from the HUES8 background wt or KO for
SIX2. n=4. ns by unpaired two-way t test. Error bars represent s.e.m.

Figure S3. Additional RNA sequencing analysis. Related to Figure 3. (A) Enriched gene sets for important β cell
processes from the Molecular Signatures Database. (B) Additional enrichment plots. These are made with genes from

the individual custom gene sets comprising 76 genes identified in Veres et al (Veres et al., 2019) and the top 424 genes
identified in Nair et al (Nair et al., 2019) positively correlating with time and maturation in vitro (Tables S2-S3). (C)
Real-time PCR measurements of Stage 6 cells made with protocol 2 transduced with sh-ctrl or sh-SIX2-1 in the 10134FA background. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by two-way unpaired t test. Error bars represent
s.e.m.

Figure S4. Additional data on SIX2 KD and KO effects on SC-β cells. Related to Figure 4. (A) Insulin content
for Stage 6 cells transduced with sh-ctrl or sh-SIX2-1 in the 1013-4FA background. n=5. (B) Insulin content for Stage
6 cells wt or KO for SIX2. n=5. (C) OCR measurements for Stage 6 cells transduced with sh-ctrl or sh-SIX2-1 in the
1013-4FA background under basal conditions and after sequential injections of Oligomycin (OM), Carbonyl cyanide4-(trifluoromethoxy)phenylhydrazone (FCCP), and Antimycin A with rotenone (AA/R). n=9 for sh-ctrl and n=10 for
sh-SIX2-1. *p<0.05,***p<0.001 by two-way unpaired t test. Error bars represent s.e.m.

